Exai Bio
About:
Exai Bio is an orphan non-coding RNAs and AI-based liquid biopsy company.
Website: https://exai.bio
Top Investors: Section 32, Casdin Capital, Two Sigma Ventures
Description:
Exai Bio is a next-generation liquid biopsy company. Exai bio proprietary RNA and artificial intelligence-based liquid biopsy platform deliver clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer.
Total Funding Amount:
$67.5M
Estimated Revenue Range:
$1M to $10M
Headquarters Location:
Palo Alto, California, United States
Founded Date:
2021-01-01
Contact Email:
info(AT)exai.bio
Founders:
Babak Alipanahi, Pat Arensdorf
Number of Employees:
11-50
Last Funding Date:
2021-12-09
IPO Status:
Private
Industries:
© 2025 bioDAO.ai